Drug-related adverse events were all of mild intensity and reported in seven participants : one in the 1 g idarucizumab group ( infusion site erythema and hot flushes ) , one in the 5 g plus 25 g idarucizumab group ( epistaxis ) ; one receiving placebo ( infusion site haematoma ) , and four during dabigatran etexilate pretreatment ( three haematuria and one epistaxis ) .